Characteristics | RA Group, n = 53 | Control, n = 86 | p |
---|---|---|---|
Age, yrs | 61.71 ± 9.28 | 60.13 ± 7.86 | 0.15 |
Weight, kg | 67.18 ± 10.19 | 66.91 ± 7.88 | 0.85 |
Height, cm | 156.71 ± 6.24 | 158.01 ± 3.53 | 0.12 |
Body mass index, kg/m2 | 27.49 ± 4.82 | 26.79 ± 4.44 | 0.41 |
Years since menopause | 13.23 ± 7.97 | 11.72 ± 8.39 | 0.29 |
Disease duration, yrs | 9.4 ± 7.5 | NA | — |
Functional stage | II–III | NA | — |
DAS28 | 3.75 ± 1.47 | NA | — |
CRP, mg/dl, range | 0.4 (0.09–7.3) | NA | — |
Daily prednisone dose, mg | 6.6 ± 1.9 | NA | — |
Cumulative prednisone dose, mg | 8212 (54–73000) | NA | — |
DMARD, n (%) | NA | — | |
Methotrexate | 43 (81) | — | — |
Leflunomide | 10 (19) | — | — |
Calcium and vitamin D | 53 (100) | 83 (95.4) | — |
Bisphosphonates | 51 (96.2) | — | — |
RA: rheumatoid arthritis; NA: not applicable; DAS28: 28-joint Disease Activity Score; CRP: C-reactive protein; DMARD: disease-modifying antirheumatic drugs.